SK Biopharmaceuticals Co., Ltd. (326030.KS)
326030.KS Stock Price Chart
Explore SK Biopharmaceuticals Co., Ltd. interactive price chart. Choose custom timeframes to analyze 326030.KS price movements and trends.
326030.KS Company Profile
Discover essential business fundamentals and corporate details for SK Biopharmaceuticals Co., Ltd. (326030.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jul 2020
Employees
241.00
Website
https://www.skbp.comCEO
Dong Hoon Lee
Description
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
326030.KS Financial Timeline
Browse a chronological timeline of SK Biopharmaceuticals Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 4 Feb 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 5 Aug 2025
EPS came in at ₩390.33 matching the estimated ₩390.33, while revenue for the quarter reached ₩176.30B , missing expectations by -4.14%.
Earnings released on 7 May 2025
EPS came in at ₩298.00 falling short of the estimated ₩355.53 by -16.18%, while revenue for the quarter reached ₩144.38B , missing expectations by -8.07%.
Earnings released on 6 Feb 2025
EPS came in at ₩2.43K surpassing the estimated ₩236.84 by +925.01%, while revenue for the quarter reached ₩163.02B , beating expectations by +3.18%.
Earnings released on 8 Nov 2024
EPS came in at ₩123.00 falling short of the estimated ₩184.90 by -33.48%, while revenue for the quarter reached ₩136.60B , missing expectations by -1.58%.
Earnings released on 8 Aug 2024
EPS came in at ₩359.00 surpassing the estimated ₩87.90 by +308.42%, while revenue for the quarter reached ₩134.00B , beating expectations by +12.71%.
Earnings released on 9 May 2024
EPS came in at ₩164.00 surpassing the estimated ₩46.28 by +254.36%, while revenue for the quarter reached ₩113.97B , beating expectations by +10.61%.
Earnings released on 29 Jan 2024
EPS came in at ₩86.32 falling short of the estimated ₩184.00 by -53.09%, while revenue for the quarter reached ₩126.76B , beating expectations by +18.21%.
Earnings released on 9 Nov 2023
EPS came in at -₩235.00 surpassing the estimated -₩264.74 by +11.23%, while revenue for the quarter reached ₩90.34B , missing expectations by -2.59%.
Earnings released on 10 Aug 2023
EPS came in at -₩298.00 falling short of the estimated -₩286.06 by -4.17%, while revenue for the quarter reached ₩77.01B , missing expectations by -2.00%.
Earnings released on 11 May 2023
EPS came in at -₩30.00 surpassing the estimated -₩352.23 by +91.48%, while revenue for the quarter reached ₩60.78B , missing expectations by -18.52%.
Earnings released on 9 Feb 2023
EPS came in at -₩560.00 falling short of the estimated -₩235.37 by -137.92%, while revenue for the quarter reached ₩62.77B , missing expectations by -12.49%.
Earnings released on 10 Nov 2022
EPS came in at -₩191.00 surpassing the estimated -₩272.99 by +30.03%, while revenue for the quarter reached ₩88.83B , beating expectations by +17.28%.
Earnings released on 11 Aug 2022
EPS came in at -₩579.77 falling short of the estimated -₩375.64 by -54.34%, while revenue for the quarter reached ₩53.43B , missing expectations by -1.08%.
Earnings released on 16 May 2022
EPS came in at -₩449.55 falling short of the estimated -₩328.08 by -37.02%, while revenue for the quarter reached ₩41.14B , missing expectations by -10.23%.
Earnings released on 9 Feb 2022
EPS came in at ₩601.77 surpassing the estimated -₩497.00 by +221.08%, while revenue for the quarter reached ₩230.74B , beating expectations by +246.45%.
Earnings released on 11 Nov 2021
EPS came in at -₩565.00 , while revenue for the quarter reached ₩23.95B .
Earnings released on 10 Aug 2021
EPS came in at -₩855.51 falling short of the estimated -₩608.00 by -40.71%, while revenue for the quarter reached ₩23.97B .
Earnings released on 12 May 2021
EPS came in at ₩1.65K falling short of the estimated ₩2.00K by -17.81%, while revenue for the quarter reached ₩139.99B .
Earnings released on 8 Feb 2021
EPS came in at -₩727.00 falling short of the estimated -₩213.54 by -240.45%, while revenue for the quarter reached ₩16.08B .
Earnings released on 27 Nov 2020
EPS came in at -₩805.00 surpassing the estimated -₩805.74 by +0.09%, while revenue for the quarter reached ₩3.92B .
326030.KS Stock Performance
Access detailed 326030.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.